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Abstract 
Background: Malaria is endemic in Equatorial Guinea with stable transmission, and it remains a major cause of mor‑
bidity and mortality in children under 5 years of age. Adherence to artemisinin‑based combination therapy (ACT) as 
a first‑line treatment for uncomplicated malaria is critical to malaria control. Six years after the introduction of artesu‑
nate‑amodiaquine (AS/AQ) therapy in Equatorial Guinea, adherence to the first‑line treatment seems to be low in the 
Bata district. The factors associated with the choice of malaria treatment have not been studied previously in this area; 
therefore, this study aimed to analyse the preference and use of artemether as malaria treatment and its related fac‑
tors in the Bata district of Equatorial Guinea.
Methods: In 2013, a cross‑sectional study was conducted in the Bata district, which involved 428 households. Bivari‑
ate and multivariate statistical analyses were conducted to determine the relevance of socio‑economic, geographical, 
and behavioural factors that played a role in the preference and use of artemether as malaria treatment.
Results: Artemether was considered the best treatment for malaria by 110 caregivers (26%), and was the antimalarial 
most administrated in the Bata district. It was prescribed to 117 children (27.34%); while, only 6.78% were adminis‑
tered AS/AQ. Caregivers living ≤ 3 km from the nearest health facility were almost two times more likely to consider 
artemether as the best treatment than those living farther away (95% CI 0.31–0.86). Caregivers with at least a sec‑
ondary school education were 2.7 times more likely to consider artemether as the best treatment than those less 
educated. Children whose caregivers considered artemether the best treatment against malaria were five times more 
likely to be treated with artemether than children with caregivers who did not consider it the best (OR 5.07, 95% CI 
2.93–8.78). In contrast, children that reported weakness as a symptom were less likely to be treated with artemether 
than those with other symptoms (OR 0.47, 95% CI 0.28–0.78).
Conclusion: Caregivers, public and private health staff, and drug sellers need to understand the importance of using 
ACT to treat uncomplicated malaria and the dangers of using artemisinin monotherapy.
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Background
There are 216 million cases of malaria and more than 
445,000 related deaths per year. Most of these deaths 
occur in sub-Saharan Africa, with 97% of deaths occur-
ring in children aged less than 5 years due to Plasmodium 
falciparum malaria [1].
Malaria case management, based on an early diagno-
sis and prompt treatment with effective anti-malarial 
drugs, remains the major strategy for effective control of 
malaria. However, poor perceptions about malaria and 
poor malaria drug treatment practices have contributed 
to the emergence of widespread P. falciparum resistance 
[2]. After proving the resistance of Plasmodium to chlo-
roquine, the World Health Organization (WHO) recom-
mended the use of an artemisinin-based combination 
therapy (ACT) as the first-line treatment for uncompli-
cated malaria in 2001 [3]. Unfortunately, emergence and 
spread of artemisinin resistance has been detected in 
Southeast Asia [4] and is now threatening global malaria 
control and elimination efforts, especially in sub-Saharan 
Africa, where the disease burden is highest and systems 
for monitoring treatment compliance and containment 
of resistance are weak [5]. Adherence to this ACT first-
line treatment is critical to the success of malaria control.
Despite progress made reinforcing access to treatment, 
WHO reported that only 30% of diagnosed children 
less than 5 years old received an anti-malarial drug dur-
ing the last year, and the proportion receiving ACT was 
only 14% [1]. Many years after the introduction of ACT, 
poor access to treatment; inappropriate treatment prac-
tices such as presumptive treatment, co-medication, use 
of low quality ACT, artemisinin monotherapy and the 
expensive price of ACT persist [6]. Low use of ACT may 
increase the malaria burden and the risk of widespread 
parasite resistance and lead to treatment failure [7].
Malaria has stable transmission and is endemic in 
Equatorial Guinea [8] and remains a major cause of mor-
bidity and mortality of children under 5 years of age [9]. A 
malaria control programme was introduced in the main-
land region in 2007, under the Equatorial Guinea Malaria 
Control Initiative (EGMCI). Case management was 
improved with the distribution of free ACT to all health 
facilities and Community Health Workers (CHWs). The 
initiative was largely funded by The Global Fund to Fight 
AIDS, Tuberculosis, and Malaria (GFATM), and it was 
implemented by the government of Equatorial Guinea, 
in collaboration with several international organizations. 
The first and second line treatments for uncomplicated 
malaria in Equatorial Guinea are artesunate-amodiaquine 
(AS/AQ) and artemether/lumefantrine (AL), respec-
tively. According to the Malaria National Treatment 
Guide, intravenous artesunate injection is recommended 
for the management of severe malaria. If artesunate is 
not available, quinine and artemether should be admin-
istered until the patient recovers consciousness, then full 
AS/AQ therapy should be administrated [10]. Unfor-
tunately, with the withdrawal of the GFATM funding in 
2011, the EGMCI stopped its main activities in mainland 
Equatorial Guinea. Universal access to ACT has not been 
assured ever since [11] and no actions have been imple-
mented to improve ACT adherence in the district of 
Bata. Equatorial Guinea is one of the African countries 
with the lowest percentage of malaria cases treated with 
antimalarial medicines [12]. In 2015, WHO estimated 
there were about 310,000 malaria cases in Equatorial 
Guinea, but only 40,911 ACT delivered [1]. The use of 
oral artemisinin monotherapy was forbidden in Equato-
rial Guinea in 2014 [10].
Six years after the introduction of AS/AQ therapy 
in Equatorial Guinea, adherence to the first-line treat-
ment seems to be non-existent in the Bata district where 
there is evidence of an alarming use and preference for 
artemether monotherapy as the first choice for malaria 
treatment. The Bata population considers artemether 
the best treatment for malaria, especially in urban areas 
[13] and, according to caregiver reports, artemether is 
the anti-malarial most often administrated to children, 
regardless of where they seek treatment [14]. The use of 
artemisinin monotherapy involves serious risks because 
adherence to these relatively long treatment regimens is 
low, leading to parasite resistance and illness recrudes-
cence [15]. Detailed knowledge about the use and prefer-
ence of artemether as first choice treatment is needed in 
order to design effective actions addressed to protect the 
therapeutic life of ACT in Bata district.
Understanding the treatment behaviour and use of 
anti-malarial drugs is crucial to malaria control and 
elimination [16]. Household decisions about which drugs 
to use are usually based on prior illness and treatment 
experiences, local beliefs, understandings of illness aeti-
ologies, recognition of symptoms, influence of social 
networks, perceived effectiveness of a treatment, and 
available options [17]. Several factors may be responsi-
ble for a household’s non-adherence to first-line malaria 
treatment, including the level of education of the car-
egiver, employment, children’s ages and symptoms, the 
perception of the severity of the disease, time lapse dur-
ing the search for treatment, and the source of care [18, 
19].
Further research on the use and choice of malaria treat-
ments and its determinants is necessary to strengthen 
interventions, improve malaria case management, and 
avoid the emergence and spread of artemisinin resist-
ance. This study aimed to analyse the preference and use 
of artemether as malaria treatment and its related factors 
in the Bata district of Equatorial Guinea.
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Methods
Study area and population
Bata is the largest district of Equatorial Guinea, with 
a population of 244,264 inhabitants [17]. Despite the 
efforts made by the EGMCI, the malaria prevalence has 
remained high (41.2%) in children under 15  years old 
[20]. The District’s public health facilities comprise a net-
work of ten health centres, two rural and eight urban, and 
one regional hospital located in the city of Bata. There are 
also private health facilities in the Bata district, including 
two hospitals and about 23 clinics, all in the urban area 
of Bata city [21]. About 156 pharmacies and other drug 
sellers are located throughout the rural and urban areas 
of the District. In rural areas, where the majority of the 
population lives > 3 km from a health facility, CHWs were 
trained to manage the malaria diagnosis and treatment 
[13].
Survey design and data collection
This cross-sectional study was implemented in June–
August 2013 in the Bata district of mainland Equatorial 
Guinea. This survey was part of a project that aimed to 
provide baseline data on the prevalence of malaria, the 
genetic characteristics of P. falciparum, vectors involved 
in the transmission, and to provide information about 
malaria-related knowledge, attitudes, and practices of the 
target population.
A multistage, stratified cluster sampling strategy was 
used. Primary sampling units were rural villages and 
urban neighbourhoods, which were randomly selected 
with a probability proportional to size to improve the 
accuracy of the sample. Then, 440 households from each 
cluster were randomly selected from an updated census 
provided by the head of the village or neighbourhood.
Household caregivers were identified in each house 
with at least one child less than 15  years of age, and 
they were asked about their knowledge, attitudes, and 
treatment-seeking behaviour related to the most recent 
malaria episode in a child under their care. An open-
ended questionnaire was administered by trained field 
workers. Information regarding household social charac-
teristics was also recorded. The questionnaire was previ-
ously tested and translated into the main local language, 
Fang. Caregivers could be interviewed in Spanish or 
Fang, both official languages in the country. The details of 
the survey have been described previously [20, 21].
Data analysis
A wealth indicator variable that served as a proxy for 
socio-economic status was created with household-
owned assets, housing characteristics, and the type of 
access to water and sanitation using principal compo-
nent analysis [22, 23]. The first principal component was 
considered the summary measure of socio-economic 
status, and subsequently divided into quintiles to assign 
households to different wealth strata. A malaria knowl-
edge score was created to categorize respondents with 
poor or good knowledge, including the caregiver’s knowl-
edge about malarial transmission, disease symptoms, 
prevention, treatment for children, and treatment cen-
tres. Good or poor knowledge of malaria disease symp-
toms, transmission, and prevention was defined as scores 
above or within and below the overall median, respec-
tively [13].
Frequencies and percentages were used to summarize 
data and to assess factors related to the use of artemether 
as treatment and considering artemether the best treat-
ment. The mean and standard deviation or median and 
interquartile range were calculated for continuous vari-
ables that were or were not normally distributed, respec-
tively. Student’s t test and χ2 tests were performed for 
continuous and categorical variables, respectively. Com-
parisons with p values < 0.05 were considered signifi-
cant. Bivariate analyses of the associations between the 
independent variables and artemether, as the treatment 
received and as the malaria treatment preferred, were 
conducted using simple logistic regression. Independent 
variables that were significantly associated at the p < 0.10 
level were included in the multivariable analysis. The col-
linearity between independent variables was checked 
and when present, the variable explaining less data dis-
tribution was removed. Logistic regression models were 
obtained using a manual backward stepwise procedure. 
The adjusted odds ratio (aOR) and 95% confidence inter-
val (95% CI) were computed; p values ≤ 0.05 were con-
sidered statistically significant. The sampling design was 
considered in the analysis. Data analysis was performed 
using STATA software version 12.
Ethical approval
This study was approved by the Ministry of Health and 
Social Welfare of Equatorial Guinea and the Ethics Com-
mittee of the Spanish National Health Institute, Carlos III 
(CEI PI 22_2013-v3). Written informed consent for par-
ticipation in the study was obtained from the caregivers 
interviewed and from the heads of the households.
Results
Descriptive statistics
A total of 428 caregivers were asked what they consid-
ered the best treatment for malaria. Artemether was 
the therapy most mentioned, by 110 caregivers (25.7%); 
while, AS/AQ was only mentioned by 6.5% of caregiv-
ers. When asked about the treatment prescribed to their 
child during the last malaria episode, the anti-malar-
ial drugs most administrated were artemether to 117 
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children (27.3%) and sulfadoxine/pyrimethamine (SP) to 
59 (13.8%); while, AS/AQ was only administrated to 6.8% 
of the children. Treatment cost was also reported. Treat-
ment with artemether was more expensive than AS/AQ 
(Fig. 1), with a median costs of 10,000 (IQR:6700–18,000) 
CFA (18.7 USD) and 4000 (IQR:2000–15,750) CFA (7.5 
USD), respectively.
Considered artemether as the best treatment
Most of the caregivers that considered artemether the 
best treatment for malaria (Table 1), were aged between 
25 and 34  years (45.5%), had attended at least second-
ary school (75.5%), had a good Malaria Knowledge Score 
(60.0%) and around 74.5% of caregivers lived in urban 
areas ≤ 3  km from the nearest health facility. When 
asked about why they consider artemether the best drug 
to treat malaria, 60.9% answered that “it is the treatment 
that makes them feel better” (while other treatments have 
side-effects) and 20.9% said that “it is the treatment they 
always give to us”. Almost half of the caregivers (43.6%), 
who considered artemether the best treatment, received 
advice from a hospital or health centre (66.7%) before 
treating the last malaria episode in a child under their 
care but differences with those that did not received 
advise not reach significance.
Received artemether as treatment
Most of the 117 children treated with artemether were 
aged between 1 and 5 years (64.1%) with almost no dif-
ference in sex, most lived in urban areas (65.0%), at 
≤ 3 km from the nearest health facility (66.7%). Regard-
ing the caregivers, 65.8% were aged less than 34  years, 
66.7% had finished at least secondary school, and 57.3% 
had good Malaria Knowledge Score. Almost half of the 
caregivers (49.6%) whose child received artemether con-
sidered it the best treatment for malaria and only 7.7% 
considered AS/AQ the best. Most of the children treated 
with artemether were brought to a hospital to seek 
care (63.2%), but there was not a statistically significant 
Fig. 1 Malaria treatment costs reported by caregivers 
according to the treatment prescribed in the Bata district. SP 
sulfadoxine pyrimethamine, AL artemether‑lumefantrine, AS/AQ 
artesunate‑amodiaquine






n % n %
Caregiver age (years)
 15–24 65 20.4 21 19.1
 25–34 103 32.4 50 45.5
 35–44 61 19.2 21 19.1
 45–54 56 17.6 15 13.6
 ≥ 55 33 10.4 3 2.7 0.034
Education
 Primary school or less 174 54.7 27 24.5
 At least secondary school 144 45.3 83 75.5 0.000
Malaria knowledge
 Poor 206 64.8 44 40.0
 Good 112 35.2 66 60.0 0.000
 Area
 Rural 145 45.6 28 25.5
 Urban 173 54.4 82 74.5 0.000
Distance to nearest health facility
 ≤ 3 km 166 52.2 83 75.5
 > 3 km 152 47.8 27 24.5 0.000
Wealth quintiles
 Poorest 72 22.6 15 13.6
 Second 59 18.6 31 28.2
 Middle 64 20.1 16 14.5
 Fourth 64 20.1 23 20.9
 Richest 52 16.4 32 29.1 0.026
Delay in seeking treatment
 ≤ 24 h 124 39.0 49 44.5
 > 24 h 114 35.8 34 30.9 0.275
Have you received advice on treating malaria?
 No 230 72.3 62 56.4
 Yes 88 27.7 48 43.6 0.002
To have a malaria case in the house
 No 90 28.3 36 32.7
 Yes 201 63.2 71 64.5 0.605
 Sex of child 318 110
 Male 158 49.7 64 58.2
 Female 160 50.3 46 41.8 0.124
Age group (years)
 < 1 40 12.6 21 19.1
 1–5 191 60.1 60 54.5
 > 5 87 27.4 29 26.4 0.236
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difference when compared with the other sources of care. 
Almost 60.0% of the children treated with artemether 
sought treatment during the first 24 h after the onset of 
symptoms (Table 2).
The three malaria symptoms most mentioned by the 
caregivers of children that received artemether were fever 
(84.6%), nausea (26.5%), and weakness (23.9%). Nausea 
and weakness were the only two symptoms significantly 
associated with receiving artemether treatment. The 
signs and symptoms mentioned by caretakers of children 
treated with artemether are presented in Fig. 2.
Factors related to the treatment preferences
Once adjusted for other variables, only the educational 
degree, Malaria Knowledge Score, and the distance to 
the health facility remained significant. Household car-
egivers that lived ≤ 3  km from the nearest health facil-
ity were 1.9 times more likely to consider artemether the 
best treatment for a child with malaria than those living 
farther away after adjusting for other variables (95% CI 
0.31–0.86). Also, caregivers with at least a secondary 
school education who had good malaria knowledge score 
were 2.7 and 1.9 times more likely to consider artemether 
the best treatment than those with less education and 
malaria knowledge, respectively (Table 3).
Factors related to being treated with artemether
Children with weakness were 2.1 less likely to have 
received artemether, after adjustment for other vari-
ables; while, children whose caregivers had good malaria 
knowledge score were 1.8 times more likely to have 
received artemether than children with caregivers with 
poor malaria knowledge. Children whose caregivers con-
sidered artemether the best treatment for malaria were 5 
times more likely to be treated with artemether (Table 4).
Discussion
The use of artemisinins, such as artemether, as the first 
choice treatment for malaria is a dangerous practice that 
could increase the emergence and spread of artemisinin 
resistance and reduce the possibilities of malaria control. 
Table 2 Characteristics of children treated with artemether 
and their households in the Bata district
Artemether p value
No Yes
n % n %
Age group (years)
 < 1 49 15.8 12 10.3
 1–5 176 56.6 75 64.1
 > 5 86 27.7 30 25.6 0.253
Sex of child
 Male 155 49.8 67 57.3
 Female 156 50.2 50 42.7 0.171
Area
 Rural 132 42.4 41 35.0
 Urban 179 57.6 76 65.0 0.165
Distance to nearest health facility
 ≤ 3 km 171 55.0 78 66.7
 > 3 km 140 45.0 39 33.3 0.029
Wealth quintiles
 Poorest 72 23.2 15 12.8
 Second 59 19.0 31 26.5
 Middle 64 20.6 16 13.7
 Fourth 64 20.6 23 19.7
 Richest 52 16.7 32 27.4 0.008
To have a malaria case in the house 195
 No 90 28.9 36 30.8
 Yes 194 62.4 78 66.7 0.983
Caregiver characteristics
 Caregiver age
  15–24 62 19.9 24 20.5
  25–34 100 32.2 53 45.3
  35–44 58 18.6 24 20.5
  45–54 58 18.6 13 11.1
  ≥ 55 33 10.6 3 2.6 0.008
Education
 Primary School or less 162 52.1 39 33.3
 At least secondary school 149 47.9 78 66.7 0.001
Malaria knowledge
 Poor 200 64.3 50 42.7
 Good 111 35.7 67 57.3 0.000
Best treatment
 Artemether 52 16.7 58 49.6 0.000
 AS/AQ 19 6.1 9 7.7 0.555
Source of treatment
 Pharmacy 26 8.4 13 11.1
 Traditional healer 1 0.3 0 0.0
 Private doctor 44 14.1 14 12.0
 Health centre 52 16.7 15 12.8
 Hospital 123 39.5 74 63.2
 CHW 2 0.6 0 0.0




n % n %
Delay
 ≤ 24 h 120 51.9 53 58.9
 > 24 h 111 48.1 37 41.1 0.262
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Fig. 2 Symptoms of children treated with artemether
Table 3 Factors associated with  the  preference 
for artemether as treatment by multiple logistic regression







 Urban 2.45 (1.50–4.01)
Distance to nearest health facility
 ≤ 3 km
 > 3 km 0.36 (0.22–0.58) 0.52 (0.31–0.86)
Wealth quintiles
 Poorest
 Second 2.15 (0.98–4.69)
 Middle 2.22 (1.00–4.95)
 Fourth 2.38 (1.09–5.21)
 Richest 3.47 (1.59–7.60)
Caregiver age (years)
 15–24
 25–34 1.50 (0.82–2.74)
 35–44 1.07 (0.53–2.15)
 45–54 0.83 (0.39–1.77)
 ≥ 55 0.28 (0.08–1.04)
Education
 Primary school or less
 Secondary school or 
more
3.71 (2.24–6.16) 2.74 (1.74–4.30)
Malaria knowledge
 Poor
 Good 2.76 (1.75–4.36) 1.99 (1.27–3.12)
Did you receive advice to treat malaria?
 No
 Yes 2.02 (1.28–3.19)
Table 4 Factors associated with  receiving artemether 
as treatment by multiple logistic regression





Distance to nearest health facility
 ≤ 3 km
 > 3 km 0.61 (0.39–0.96)
Wealth quintiles
 Poorest
 Second 2.52 (1.23–5.19)
 Middle 1.20 (0.55–2.63)
 Fourth 1.73 (0.82–3.61)
 Richest 2.95 (1.42–6.14)
Symptoms
 Nausea 1.88 (1.13–3.15)
 Weakness 0.57 (0.35–0.94) 0.47 (0.28–0.78)
Caregiver age (years)
 15–24
 25–34 1.37 (0.77–2.44)
 35–44 1.07 (0.55–2.09)
 45–54 0.58 (0.27–1.25)
 ≥ 55 0.23 (0.06–0.87)
Education
 Primary School or less





 Good 2.41 (1.55–3.76) 1.83 (1.14–2.92)
 Best treatment
 Artemether 4.90 (2.97–8.06) 5.07 (2.93–8.78)
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The lack of adherence to a malaria first line treatment has 
been described before [24], but the treatments used were 
former first-line therapies, including chloroquine, amodi-
aquine, SP, or other artemisinin-based combinations [16, 
24–26]. For the first time, wide use of artemether as the 
first-choice treatment against malaria is described in sub-
Saharan Africa.
The P. falciparum resistance to artemisinin and its 
derivatives has spread in Southeast Asia and is threating 
malaria control efforts in sub-Saharan Africa. K13-pro-
peller mutations have become the molecular marker of 
artemisinin-resistance detection. This mutation has been 
found in a Chinese migrant worker returned home from 
Equatorial Guinea [27], but studies has not yet detected 
the k13 mutations linked with artemisinin resistance in 
the local population [28]. A therapeutic efficacy study is 
in progress in Equatorial Guinea. This study will include 
a molecular analysis of the samples to detect delayed par-
asite clearance of artemisinin. The correct interpretation 
of results from this study will require knowing the real 
pressure of artemisinins treatments in the area.
In the Bata district of Equatorial Guinea, the educa-
tional level of the caregivers, living close to a health facil-
ity, and the caregiver’s knowledge about malaria were 
factors associated with considering artemether the best 
treatment. Moreover, the caregiver’s knowledge about 
malaria and considering artemether the best treatment 
were associated with receiving artemether as treatment 
in the district.
The low use of ACT in Africa is usually related to the 
caregiver’s limited awareness about malaria [29], low 
socioeconomic level, and rurality [30]; although, in the 
Bata district, the profile of caregivers whose children 
received artemether was very different. Caregivers were 
younger than 35  years, had at least a secondary school 
education, lived in urban areas no further than 3  km 
from a health facility, and had a good Malaria Knowledge 
Score, a profile very similar to that of the caregivers who 
preferred artemether as treatment.
In the Bata district, living near a health facility seemed 
to be an important factor associated with considering 
artemether the best treatment. At the same time, con-
sidering artemether the best therapy was associated with 
receiving artemether as treatment. It seems that patients’ 
preferences were influencing the treatment received. 
Other studies have identified that the prescriptive prac-
tices of health workers frequently correspond with the 
expectations of the community, who want prompt recov-
ery and injectable medications [17]. Furthermore, being 
in the area of a health care facility in the Bata district 
seemed to influence patients’ treatment preferences. 
Usually, health workers are most influential in caregivers’ 
decisions about the illness, when consulted [31].
Decisions about the choice of treatment are also based 
on perceived therapy effectiveness [17]. Artemether rap-
idly eliminates asexual parasite stages and early sexual 
forms of falciparum malaria, producing a rapid clinical 
and parasitological response [32, 33]. Moreover, in the 
Bata district, the idea that AS/AQ has adverse effects is 
deeply rooted in the whole population, despite the intro-
duction of a single dose combination in 2012. Some-
times practitioners either refuse to prescribe AS/AQ to 
patients or they reduce the drug dosage to minimize the 
adverse effects [16]. Receiving artemether as treatment in 
the Bata district did not seem to be related to particular 
symptoms, which would be expected if the therapy was 
used according to the severity of the child, as suggested 
in the National Malaria Treatment Guide [10]. On the 
contrary, weakness was the only symptom associated 
with artemether, but children with weakness were 2.14 
less likely to receive artemether therapy. Further research 
on health workers’ practices related to malaria treatment 
administration is needed to understand the patterns and 
reasons for prescribing artemether.
Treatment costs should be a key issue in deciding 
which antimalarial to treat with, especially among rural 
households [30]. However, in the Bata district, receiving 
artemether was more expensive than first-line AS/AQ. It 
seems that the high cost of artemether versus the cost of 
AS/AQ is not a determining factor in the preference for 
treating with artemether.
Caregivers who know that ACT is the government-
recommended antimalarial are usually more likely to 
demand a first-line anti-malarial [29]. The extended pref-
erence for using artemether to treat malaria in the Bata 
district, regardless of where treatment was received [14], 
indicates it is necessary to promote the use of ACT at 
household and practitioner levels.
This study has some limitations. First, this is a cross 
sectional study conducted only in the Bata district; 
thus, the findings might not be generalizable to the 
whole country. Also, results are based on the treatment 
reported by caregivers and not by direct observation. 
However, artemether was not included as an answer in 
the questionnaire and was still mentioned as a preferred 
and received treatment more than a hundred times.
Conclusions
This study identified the behaviours and associated fac-
tors that play important roles in the preference and use 
of artemether as malaria treatment. To improve the 
compliance with malaria first-line treatment, caregiv-
ers, public and private health staff, and drug distributers 
need to understand the importance of using ACT to treat 
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uncomplicated malaria and the dangers of using arte-
misinin monotherapy.
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